FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Group",
  "id": "370701",
  "meta": {
    "versionId": "2",
    "lastUpdated": "2025-05-28T13:31:45.515Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-exposure-definition"
    ]
  },
  "language": "en",
  "text": {
    "status": "empty",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
      "valueMarkdown": "Glucagon Nasal Powder (Experimental) [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370701. Revised 2025-05-28. Available at: https://fevir.net/resources/Group/370701. Computable resource at: https://fevir.net/resources/Group/370701#json."
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail": {
        "name": "Brian S. Alper, MD, MSPH"
      }
    },
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Group/370701",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "370701",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "title": "Glucagon Nasal Powder (Experimental)",
  "status": "active",
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description": "Example of ConceptualExposureDefinition combining M11 IGBJ Protocol Example Eligibility Criteria PLUS exposure to Glucagon Nasal Powder",
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "type": "person",
  "membership": "conceptual",
  "combinationMethod": "all-of",
  "characteristic": [
    {
      "code": {
        "text": "Member of"
      },
      "valueReference": {
        "reference": "Group/267506",
        "type": "Group",
        "display": "M11 IGBJ Protocol Example Eligibility Criteria"
      },
      "exclude": false,
      "description": "Member of M11 IGBJ Protocol Example Eligibility Criteria"
    },
    {
      "code": {
        "text": "Assigned to"
      },
      "valueCodeableConcept": {
        "text": "Glucagon Nasal Powder (Experimental) A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally."
      },
      "exclude": false,
      "description": "assigned to Glucagon Nasal Powder"
    }
  ]
}